Em meio à polêmica envolvendo a abertura de um processo contra a OpenAI, a Apple enviou cartas — mais precisamente advertências legais individuais — para dezenas de funcionários da empresa de inteligência artificial.

Segundo o Financial Times, cerca de 40 ex-funcionários da Apple que hoje trabalham na OpenAI receberam as cartas. Nela, a Maçã solicita reuniões com seus advogados, exigindo a preservação de documentos e comunicações.

A empresa, vale recordar, acusa alguns dos seus ex-funcionários de roubar planos secretos de hardware e entregá-los à OpenAI — que trabalha atualmente com o ex-chefão de design da Apple, Jony Ive, para desenvolver seus próprios dispositivos.

O envio desse tipo de documento é descrito pelo FT como uma prática agressiva. Nos documentos judiciais, a Maçã argumenta que as evidências que possui representam apenas a “ponta do iceberg” em relação à conduta da OpenAI.

Tendo denunciado diretamente a empresa e dois de seus ex-funcionários, a Apple afirma que todo o negócio de hardware da OpenAI estaria comprometido pelo uso de seus segredos comerciais de forma ilegal.

Procuradas pelo jornal, tanto a Apple quanto a OpenAI recusaram-se a comentar a reportagem.

In recent years, the use of virtual reality (VR) in clinical psychology has surged, offering innovative approaches to treat some of the most challenging mental health conditions. A groundbreaking study published in 2026 by Glenthøj, Vernal, Mariegaard, and colleagues in Schizophrenia examines an essential question: can emotion regulation be identified as a primary mechanism driving the efficacy of virtual reality-assisted therapy for auditory hallucinations? This investigation, a secondary analysis stemming from the CHALLENGE randomized clinical trial, shines a new light on how immersive technologies might not just help manage symptoms but actively transform the neuropsychological processes underlying psychosis.

Auditory hallucinations, or hearing voices that are not present, are among the most debilitating symptoms experienced by individuals with schizophrenia and related disorders. Conventional treatments, while somewhat effective, often leave patients with residual symptoms, significantly impairing their quality of life. The advent of VR-assisted therapy offers a promising frontier by immersing patients in controlled, yet highly realistic environments where they can confront and modulate their hallucinatory experiences under therapeutic guidance. The CHALLENGE trial represents one of the largest and most comprehensive efforts to rigorously assess these interventions and tease apart the psychological factors mediating their success.

This study’s unique contribution lies in its focus on emotion regulation as the potential key mechanism of therapeutic change. Emotion regulation refers to the complex set of cognitive and behavioral processes through which individuals influence their emotional experiences, expressions, and responses. In psychosis, dysregulated emotional reactions to hallucinations can exacerbate distress and dysfunction, creating a vicious cycle of increased symptom severity. By using VR to simulate hallucinatory voices within a safe environment, patients may practice adaptive emotion regulation strategies that reduce the impact of their symptoms in daily life.

The methodology underpinning this secondary analysis involved sophisticated statistical modeling to track changes in patients’ emotion regulation capabilities alongside reductions in hallucination severity and distress over the course of VR therapy. Participants underwent multiple VR sessions designed to confront hallucinations through interactive avatars representing the voices, coupled with real-time coaching in cognitive reappraisal, mindfulness, and distress tolerance techniques. This allowed researchers to dynamically examine how improvements in managing emotions corresponded with clinical outcomes, offering evidence for causality rather than mere correlation.

Findings suggest that emotion regulation improvements significantly mediated the reduction of hallucination-related distress and overall symptom burden. Patients who demonstrated greater gains in their ability to reinterpret and modulate negative emotional responses to the voices subsequently reported notably diminished auditory hallucination severity. Such results provide compelling experimental support for emotion regulation as a central therapeutic mechanism in VR-assisted interventions, marking a pivotal advancement in psychosis treatment models.

From a neuroscientific perspective, these results align well with emerging understandings of the neural substrates involved in psychosis. Dysfunction within prefrontal-limbic circuits, which govern emotional control and executive function, is thought to underpin many psychotic symptoms. VR therapy may promote neuroplasticity within these networks by encouraging patients to engage in adaptive emotional strategies repeatedly in immersive, salient contexts, effectively rewiring maladaptive patterns that perpetuate hallucinations and distress.

Moreover, the immersive and interactive attributes of VR make it uniquely suited to facilitate experiential learning in emotion regulation. Unlike traditional talk therapy, VR creates visceral, multi-sensory exposures that can evoke authentic emotional responses. This experiential intensity may enhance the encoding and generalization of therapeutic gains, supporting transfer of emotion regulation skills into everyday challenging encounters with hallucinations. The personalized, graded nature of VR exposures further tailors treatment to individual patients’ needs and tolerance levels, optimizing clinical impact.

Importantly, this study also addresses critical questions about the durability and specificity of these effects. Secondary analyses revealed that emotion regulation gains were maintained at follow-up assessments several months post-therapy, suggesting lasting positive neuropsychological change rather than transient symptom suppression. Additionally, these improvements were specific to emotion regulation constructs rather than generalized cognitive or attentional abilities, underscoring the targeted nature of VR’s therapeutic impact.

These insights offer profound clinical implications. By pinpointing emotion regulation as a core mechanism, future interventions can increasingly focus on honing these skills within VR platforms, potentially integrating neurofeedback, bio-sensing, or adaptive difficulty adjustments to accelerate recovery. Furthermore, emotion regulation could serve as a predictive biomarker to identify patients most likely to benefit from VR-assisted therapy, enabling precision psychiatry approaches tailoring treatment plans according to individual emotional processing profiles.

The study’s implications extend beyond psychosis treatment per se, offering a conceptual framework for utilizing VR in other psychiatric domains where emotional dysregulation plays a pivotal role, such as anxiety disorders, PTSD, and depression. By demonstrating how immersive technologies can catalyze emotion regulation neural circuits, this research paves the way for wide-reaching applications of VR as a transformative therapeutic tool in mental health care.

Nevertheless, the authors acknowledge ongoing challenges in scaling VR therapies, including technological accessibility, patient engagement variability, and the need for standardized protocols to ensure intervention fidelity. Ethical considerations surrounding the intensity of VR experiences and the safeguarding of vulnerable patients also merit ongoing scrutiny as this field evolves. Continued randomized trials with larger samples and diverse populations will be essential to consolidate evidence and inform best practice guidelines.

In summary, the CHALLENGE trial secondary analyses present a landmark investigation revealing that emotion regulation improvements are not merely outcomes but active mechanisms driving symptom improvement in VR-assisted therapy for auditory hallucinations. This discovery heralds a new era where immersive therapeutics grounded in robust neuropsychological theory have the potential to reshape mental health treatment paradigms fundamentally.

As virtual reality continues to infiltrate clinical settings, the intersection of technology and psychology promises unprecedented opportunities to unlock healing mechanisms once obscured by conventional approaches. This pioneering research by Glenthøj et al. charts a visionary pathway—one where harnessing the brain’s intricate emotional machinery through immersive digital environments can rewrite the narratives of suffering for individuals grappling with psychosis worldwide.

The convergence of virtual environments, cognitive science, and clinical innovation showcased in this work highlights a future where mental illness is not merely managed but dynamically transformed through mechanistic precision in therapy design. For patients burdened by the relentless voices of auditory hallucinations, the promise of VR-assisted emotion regulation offers a beacon of hope toward reclaiming agency, resilience, and meaning in their lives.

---

Subject of Research: Emotion regulation as a mechanism of change in virtual reality-assisted therapy for auditory hallucinations.

Article Title: Is emotion regulation a mechanism of change in virtual reality-assisted therapy for auditory hallucinations? Secondary analyses of the CHALLENGE randomized clinical trial.

Article References:
Glenthøj, L.B., Vernal, D.L., Mariegaard, L.S. et al. (2026). Is emotion regulation a mechanism of change in virtual reality-assisted therapy for auditory hallucinations? Secondary analyses of the CHALLENGE randomized clinical trial. Schizophrenia. https://doi.org/10.1038/s41537-026-00779-2

Image Credits: AI Generated

In a groundbreaking advance poised to transform the landscape of age-related immune decline, University College London (UCL) researchers are spearheading a pioneering clinical trial aimed at rejuvenating worn-out T cells through an innovative immune restoration therapy. This Phase 1 first-in-human study will explore the therapeutic potential of metabolically resetting exhausted or senescent T cells, a subset of immune cells that accumulate with age and chronic disease and lose their robustness in coordinating immune responses. The initiative promises to reopen avenues for combating a spectrum of diseases, including cancer, HIV, and neurodegenerative disorders like dementia, by profoundly modifying the immune system’s intrinsic capacity to defend and repair.

Central to the research is the recognition that immune ageing, characterized by the progressive dysfunction and decline in immune cell performance, is a key factor leading to increased vulnerability in the elderly and those with chronic infections. T cells, particularly the CD4+ subtype—often regarded as the conductors of the immune orchestra—become less effective with time, diminishing the immune system’s ability to coordinate defenses accurately. These cells, rendered senescent or exhausted, exhibit impaired proliferation, cytokine production, and cytotoxic activity, undermining responses to pathogens, malignancies, and cellular damage.

The novel therapy, developed by SenTcell, a biotech startup founded by Dr. Alessio Lanna from UCL Medicine, employs a liquid formulation administered intramuscularly akin to conventional vaccines. This delivery method facilitates patient-friendly administration while targeting key metabolic pathways within dysfunctional T cells. By reprogramming the intracellular environment of these immune cells, the treatment aims to restore youthful functional properties, including enhanced proliferative capacity and efficient pathogen recognition, thereby revitalizing the immune system’s broad protective functions.

Dr. Lanna explains that although antiretroviral advancements have significantly improved lifespans for individuals living with HIV, many still experience premature immune ageing. Similar patterns of immune exhaustion are also detected in cancer patients and other chronic disease cohorts. The imminent clinical trial represents a critical stepping stone towards verifying whether exhausted immune cells can be safely and effectively rejuvenated in human subjects, with the potential to redefine therapeutic paradigms for diseases rooted in immune dysregulation.

At the molecular level, one of the intriguing aspects under investigation involves the role of telomeres—protective caps on chromosome ends whose shortening serves as a hallmark of biological ageing. Laboratory studies have suggested that rejuvenated CD4+ T cells may release telomere-containing extracellular structures, whimsically termed “telomere Rivers,” into the bloodstream. The presence and behavior of these structures might offer novel insights into how restored immune cells influence systemic health, extending their benefits beyond immediate immune niches to broader tissue health. Although this phenomenon has yet to be validated in human clinical contexts, it highlights the sophisticated interplay between immune rejuvenation and organismal aging.

The clinical trial enjoys regulatory support from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) through its Innovative Licensing and Access Pathway (ILAP), underscoring the therapy’s potential to meet the pressing unmet medical needs associated with immune senescence. This endorsement accelerates development timelines and affirms the significance of targeting immune metabolic dysfunction as a viable therapeutic strategy.

Participants in the upcoming Phase 1 trial will be meticulously selected adults exhibiting characteristics of immune dysfunction, including evidence of premature immune ageing or persistent viral infections. Comprehensive immune profiling will be conducted before and after therapeutic administration to discern immunological changes and safety outcomes. Although the initial focus is on evaluating biological activity and tolerability, successful results could pave the way for advanced trials assessing clinical efficacy.

Unlike conventional treatments that combat diseases by targeting individual pathogens or tumor cells directly, this therapy seeks to recalibrate the immune system itself—restoring its intrinsic resilience and regenerative functionality. Such a paradigm shift holds profound implications; by enhancing the immune system’s natural defensive repertoire, it may afford broad-spectrum protection and facilitate healthier ageing trajectories.

Beyond chronic infections like HIV and cancer, this approach could ultimately apply to autoimmune disorders characterized by immune exhaustion, wherein overly active yet dysfunctional immune cells drive pathology. Immune rejuvenation strategies offer a novel means of restoring balance without broadly suppressing immune activity, potentially mitigating disease progression while improving quality of life.

This research aligns with a growing global focus on understanding the cellular and molecular underpinnings of ageing and immune decline. By intervening at the level of T cell metabolism and function, scientists hope to extend not only lifespan but healthspan—preserving cognitive and physical function while reducing susceptibility to infections, cancer, and degenerative diseases.

As UCL celebrates two centuries of academic excellence and innovation, this project embodies the institution’s commitment to translating bold scientific ideas into therapies capable of reshaping medicine. If validated through clinical trials, this immune rejuvenation therapy could herald a transformative era in treating age-associated diseases, offering hope for millions affected by immune dysfunction worldwide.

Subject of Research: People
Article Title: Immune Rejuvenation: UCL’s Pioneering Trial Targets T Cell Exhaustion to Combat Age-Related Immune Decline
News Publication Date: Not provided
Web References: www.ucl.ac.uk
References: Not provided
Image Credits: Not provided
Keywords: Immune ageing, T cell exhaustion, CD4+ T cells, immune rejuvenation, senescent immune cells, telomeres, immune dysfunction, chronic disease, HIV, cancer, metabolic resetting, Phase 1 clinical trial

A groundbreaking clinical trial is underway at Leicester, spearheaded by leading researchers aiming to revolutionize treatment options for patients afflicted with mesothelioma, a particularly rare yet aggressive form of cancer. This innovative research offers a glimmer of hope to those affected, potentially extending their survival and enhancing quality of life by tailoring therapies to individual genetic profiles.

Mesothelioma arises predominantly in the linings of the lungs or abdomen and is intimately connected to asbestos exposure, a factor that has rendered this malignancy notoriously difficult to treat. Despite approximately 2,700 new diagnoses annually in the UK, prognosis remains grim, with survival rates and available treatment strategies offering limited success. Traditional therapies fail to adequately address the biological heterogeneity of this cancer, underscoring the urgent need for novel, personalized interventions.

Central to this trial, known as SELECTmeso1, is the use of targeted cancer therapies designed to exploit specific genetic vulnerabilities within tumor cells. This approach addresses the problem of variable treatment efficacy by stratifying patients based on identifiable genetic biomarkers, thus aligning therapeutic strategies with the molecular underpinnings of each patient’s disease. Trials like SELECTmeso1 embody the forefront of precision oncology, promising more effective and less toxic interventions.

The project is a collaboration between esteemed institutions including the NIHR Biomedical Research Centres in Leicester and Southampton, with the Southampton Clinical Trials Unit managing operations and oversight. Backed financially by Asthma + Lung UK, this research initiative emphasizes the growing recognition within the medical community of the importance of precision medicine in oncology, especially for diseases with limited therapeutic options like mesothelioma.

Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester and lead investigator, highlights the crux of the personalized treatment paradigm: understanding the cancer’s unique genetic landscape. Nearly 50% of mesothelioma patients exhibit a deletion of the MTAP gene, a genetic anomaly that is intricately linked with more aggressive tumor behavior and resistance to conventional therapies. This genetic deletion simultaneously presents a distinctive therapeutic target.

The trial focuses on exploiting the absence of the MTAP gene to disrupt the cancer cells’ growth machinery selectively. In healthy cells, the MTAP gene is involved in critical metabolic pathways, but its deletion in cancer cells creates a biochemical dependency that can be targeted pharmacologically. The investigational drug, Navlimetostat (also referenced as BMS-986504), developed by pharmaceutical giant Bristol Myers Squibb, is a first-in-class PRMT5 inhibitor designed to exploit this metabolic vulnerability, thereby selectively inducing cancer cell death while sparing healthy tissue.

Navlimetostat operates by inhibiting protein arginine methyltransferase 5 (PRMT5), an enzyme crucial to the survival of cancer cells deficient in MTAP. By blocking PRMT5, Navlimetostat disrupts methylation-dependent processes vital to tumor cell proliferation and survival, effectively ‘starving’ the cancer at a molecular level. Early phase studies in other malignancies have shown promising anti-tumor activity and manageable safety profiles, laying a robust foundation for its evaluation in mesothelioma.

The SELECTmeso1 phase of the trial recruits patients with relapsed mesothelioma who test positive for the MTAP gene deletion. The trial administers Navlimetostat orally in three-week cycles, continuing up to six months. Researchers monitor both tumor response and patient tolerance meticulously, aiming to affirm the drug’s efficacy and safety within this highly specific patient subgroup.

This trial represents the initial stage of a larger adaptive platform study intending to evaluate multiple targeted agents against various genetic biomarkers across the spectrum of mesothelioma cases. By adopting a platform model, SELECTmeso aims to streamline clinical investigation, allowing simultaneous testing of several therapeutic candidates tailored to genetic signatures in patients’ tumors, thereby accelerating the pace of discovery and clinical translation.

Looking to the future, the platform design will incorporate molecular profiling of tumor samples to guide patient enrollment across sub-trials, each exploring a drug matched to a distinct biomarker. Such precision trials could transform the clinical landscape, enabling oncologists to offer bespoke therapies with improved outcomes versus the current ‘one-size-fits-all’ approach. Through this strategy, SELECTmeso1 pioneers a new chapter in mesothelioma treatment.

Dr. Samantha Walker of Asthma + Lung UK emphasizes the transformative potential of this research, especially given the dismal survival statistics and lack of curative options for mesothelioma patients. The advancement of targeted therapies has altered the natural history of multiple cancers, and the hope is that SELECTmeso1 will similarly deliver breakthroughs for this challenging disease, ultimately informing standard clinical practice worldwide.

The trial has already commenced recruitment at Leicester Royal Infirmary and will expand to ten additional UK hospitals, enrolling up to 30 patients for this initial evaluation. If successful, this could lay the groundwork for larger, practice-changing trials and establish a template for personalized cancer treatment paradigms not only for mesothelioma but also for other malignancies characterized by genetic heterogeneity.

In sum, the SELECTmeso1 trial exemplifies the cutting-edge intersection of genomics and oncology, demonstrating how understanding cancer’s molecular vulnerabilities can inform smarter, targeted treatments. It embodies the hope and progress achievable through collaborative research, innovative drug design, and precision medicine to improve survival and quality of life for patients facing devastating diagnoses.

---

Subject of Research: People

Article Title: Personalized Targeted Therapy Trial for Mesothelioma Opens New Frontiers in Cancer Treatment

News Publication Date: Not explicitly stated in source content

Web References:

• Leicester Biomedical Research Centre
• SCTU website
• Asthma + Lung UK
• MiST Trial Article
• CONFIRM Trial News
• NERO Trial News

References:
Cancer Research UK statistics on mesothelioma incidence and survival
Details of Navlimetostat (BMS-986504) as a first-in-class PRMT5 inhibitor by Bristol Myers Squibb

Image Credits: University of Leicester

Keywords: Mesothelioma, Targeted therapy, Personalized medicine, MTAP gene deletion, Navlimetostat, PRMT5 inhibitor, Clinical trial, Cancer research, Genetic biomarkers, Precision oncology, Cancer treatment, Drug development

A recent clinical investigation into the impact of prone positioning on infants suffering from moderate to severe bronchiolitis has brought new insights into pediatric respiratory care. Bronchiolitis, an acute infection of the lower respiratory tract commonly caused by respiratory syncytial virus (RSV), presents a significant healthcare challenge worldwide, particularly among infants. The study specifically targeted infants receiving high-flow nasal cannula (HFNC) therapy, a common supportive treatment designed to improve oxygenation and reduce respiratory effort. Despite its widespread use, the efficacy of adjunctive positioning techniques like prone positioning in this population has remained uncertain until now.

The trial explored whether placing infants in the prone position—lying on their stomachs—could influence clinical outcomes, specifically by reducing the escalation of care. Escalation of care represents clinical deterioration requiring increased respiratory support, such as moving from HFNC to mechanical ventilation or intensive care admission. The physiological rationale behind prone positioning lies in its known benefits in improving ventilation-perfusion matching, enhancing lung mechanics, and optimizing secretion clearance. These effects have been well-documented in adult acute respiratory distress syndrome (ARDS) management, yet pediatric evidence remains limited.

In the conducted study, infants with moderate to severe bronchiolitis under HFNC support were randomized to receive either prone positioning or continue with standard positioning protocols. Researchers meticulously monitored clinical outcomes, including respiratory parameters, oxygenation indices, and the need for escalating respiratory support over the treatment course. The cohort was carefully selected to include infants representing a range of disease severities, thereby ensuring the findings would be broadly applicable to clinical practice.

Contrary to expectations driven by adult data and mechanistic theories, the results revealed no statistically significant reduction in care escalation rates associated with prone positioning in this infant population. The observed odds ratio exhibited a wide 95% confidence interval, indicating variability and uncertainty around the estimate. This statistical phenomenon suggests that while the study failed to demonstrate definitive benefit, it did not conclusively exclude the possibility that certain subgroups might still derive clinical advantage from this intervention.

The ambiguity exposed by the confidence intervals underscores the complex interplay of factors influencing respiratory mechanics and disease progression in bronchiolitis. The heterogeneity of this disease, rooted in diverse viral etiologies and varying host immune responses, may attenuate the effects of positional changes on lung function. Moreover, compliance with prone positioning protocols can be particularly challenging in infants, owing to safety concerns and caregiver adherence, potentially diluting any therapeutic effect.

Physiologically, the application of high-flow nasal cannula therapy delivers heated and humidified oxygen at flow rates sufficient to generate a mild positive end-expiratory pressure (PEEP), which helps maintain alveolar patency. Prone positioning theoretically complements this by redistributing ventilation, reducing dorsal lung atelectasis, and improving secretion mobilization. However, the dynamic respiratory mechanics of infants, coupled with the distinct pathophysiology of bronchiolitis characterized primarily by airway inflammation and mucus plugging, may limit the translation of these theoretical benefits into clinical outcomes.

In reviewing the methodological aspects, the study was conducted with rigorous adherence to randomized controlled trial protocols. Blinding was implemented where feasible, and standardized clinical criteria dictated escalation of care, thereby minimizing potential biases. The statistical power and sample size calculations accounted for anticipated effect sizes based on previous smaller studies, yet the results accentuated the need for larger, multicentric trials to verify findings and identify responsive patient subsets.

The absence of clear benefit does not diminish the value of prone positioning as a component of critical care but rather refines its role within the therapeutic armamentarium for bronchiolitis. Clinical decisions must integrate a nuanced understanding of individual patient factors, balancing potential physiological advantages against logistical and safety considerations. Additionally, continued research investigating adjunctive therapies, including pharmacologic agents and alternative respiratory support modalities, remains imperative to improve outcomes for this vulnerable population.

This investigation is particularly timely given the ongoing global burden of bronchiolitis and the frequent hospitalization of infants due to severe respiratory distress. Optimizing non-invasive interventions like HFNC and positioning could significantly impact healthcare resource utilization and patient morbidity if proven effective. Until then, prudent clinical judgment guided by evolving evidence must steer treatment approaches.

Future studies should employ advanced imaging and respiratory monitoring techniques such as electrical impedance tomography and lung ultrasound to elucidate the mechanistic effects of prone positioning on infant lung ventilation and perfusion patterns. Stratification by viral etiology, age, and baseline respiratory status could also uncover subpopulations more amenable to positional interventions. Furthermore, integrating caregiver education and safety protocols will enhance feasibility and adherence, potentially amplifying clinical benefits.

In summary, the recent multicenter randomized trial encompassing infants with moderate to severe bronchiolitis on high-flow nasal cannula support indicates that prone positioning does not significantly reduce the risk of escalation of care. Nevertheless, the wide confidence intervals highlight that this evidence is not conclusive, and further meticulously designed research is warranted. Advancing the understanding of respiratory mechanics and therapeutic positioning strategies in bronchiolitis remains a critical priority in pediatric medicine.

Corresponding author Dr. Florent Baudin emphasizes the necessity for ongoing critical appraisal and clinical trials to refine pediatric respiratory care practices. The study’s findings, presented at the International Congress of the European Society of Paediatric and Neonatal Intensive Care, contribute valuable data to the pediatric critical care community. Engaging clinicians, researchers, and healthcare providers in collaborative efforts will be essential to translate these insights into improved outcomes for infants affected by this common yet severe respiratory condition.

---

Subject of Research:
Prone positioning effectiveness in infants with moderate to severe bronchiolitis receiving high-flow nasal cannula therapy.

Article Title:
Not provided.

News Publication Date:
Not provided.

Web References:
Not provided.

References:
Not provided.

Image Credits:
Not provided.

Keywords:
Bronchiolitis, infants, prone positioning, high-flow nasal cannula, respiratory disorders, pediatric intensive care, respiratory support, lung mechanics, clinical research, acute infections, observational studies, medical treatments.

The breast cancer 'breakthrough' is a story of overtreatment, not a triumph of testing, says Dr Clare Craig. The truth is, the genetic test failed, but it's being rolled out anyway.

The post The Breast Cancer ‘Breakthrough’ is a Story of Overtreatment Not a Triumph of Testing appeared first on The Daily Sceptic.

The results were so promising one clinician started weeping.

Interdimensional beings are extradimensional beings, as distinct from extraterrestrials are perceived as entities in realms beyond our physical universe, governed by different principles. These beings may exist as energy or abstract forms and are common in science fiction and spiritual demonic contexts. Modern scientific language is used to make them acceptable.

This practical guide for modern powder-coated busbar assemblies outlines design considerations, material options, manufacturing methods, and testing strategies in the evaluation of insulation approaches.

© Custom Electronics Inc.

A recent conversation with an audiologist-turned-entrepreneur reveals how he used out-of-the-box thinking to design a new type of featherweight headset that protects pilots’ ears — and their wallets.

© Lee Goldberg